Mechanism of Action
PTH1R Activation
PTHrP(1-34) and PTH share the same N-terminal binding sequence for PTH1R. PTH1R is a class B GPCR that couples to Gs and Gq, increasing cAMP and intracellular calcium. In bone, PTH1R activation on osteoblasts stimulates RANKL expression, driving osteoclastogenesis and bone resorption. In kidney, PTH1R stimulates 1-alpha-hydroxylase activity, increasing active vitamin D (calcitriol) production.
Paracrine vs. Endocrine Actions
Unlike PTH (an endocrine hormone), PTHrP normally acts in a paracrine and autocrine manner in tissues including growth plates, mammary glands, placenta, and smooth muscle. Pathologically, tumor-derived PTHrP is released into the circulation, causing systemic hypercalcemia. The mid-region and C-terminal domains of PTHrP have separate biological activities not shared with PTH.
Research Summary
Humoral Hypercalcemia of Malignancy
ClinicalPTHrP secretion accounts for approximately 80% of humoral hypercalcemia of malignancy (HHM). Anti-PTHrP antibodies and PTH1R antagonists are therapeutic strategies being evaluated. Serum PTHrP is a diagnostic marker for HHM and correlates with tumor burden and hypercalcemia severity in breast, lung, and renal cell cancers.
Anabolic Bone Effects
FDA Approved (related)Abaloparatide, a synthetic PTHrP analog optimized for bone anabolic signaling, is FDA-approved for osteoporosis. Intermittent PTH1R activation through abaloparatide or teriparatide (PTH 1-34) promotes bone formation. This anabolic effect contrasts with the catabolic bone effects of continuously elevated PTHrP in cancer.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Bone metabolism research | 1-100 nM PTHrP(1-34) | Variable | Cell culture / in vivo |
| HHM diagnostic assay | Serum PTHrP measurement | Clinical diagnostic | Immunoassay |
PTHrP itself is not therapeutically administered; abaloparatide and teriparatide are the clinical PTH1R agonists.
Interactions
Safety Profile
PTHrP is an endogenous protein with critical developmental roles. Pathological PTHrP overexpression in cancer causes hypercalcemia, which is life-threatening if untreated. Anti-PTHrP therapeutic antibodies are in development; no approved anti-PTHrP therapy exists as of 2025. Related PTH1R agonists (abaloparatide, teriparatide) carry a boxed warning for osteosarcoma risk with prolonged use.
References
- [1]Wysolmerski JJ (2012). Parathyroid hormone-related protein: an update. Journal of Clinical Endocrinology and Metabolism, 97(9), 2947-2956.
- [2]Burtis WJ et al. (1987). Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. Journal of Biological Chemistry, 262(15), 7151-7156.